GLP-1
Pavlovic et al., 2019), which involves at least one of the following symptoms: loss or a decreased level of consciousness, loss of memory for events before or after the injury, neurological deficits (weakness, loss of balance, changes in vision, etc.), or alterations in mental state (confusion, disorientation, slowed thinking, etc.)
Judak P, Grainger J, Goebel C, Van Eenoo P, Deventer K
But there are various factors to consider
The clinical evaluation should be genuine, not a formality, before any semaglutide prescription is written
Sept 22: Nearly two months after winning approval in the EU for Jardiance in chronic kidney disease (CKD), Eli Lilly and Boehringer Ingelheim can add CKD to the SGLT2 inhibitors label stateside too